search
Back to results

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis (BIOLUVE)

Primary Purpose

Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection

Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Fluorescein angiography
Dilated fundus examination
Toxoplasmosis serology
Anti-toxoplasmosis treatment
Anti-inflammatory treatments
Puncture in anterior chamber
Sponsored by
University Hospital, Grenoble
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional screening trial for Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection focused on measuring Toxoplasmosis, Uveitis, Chorioretinitis, Infection

Eligibility Criteria

undefined - 18 Years (Child, Adult)Does not accept healthy volunteers

Inclusion Criteria:

  • Age over 18 years
  • Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
  • Persons affiliated to national social security

Exclusion Criteria:

  • Pregnant, parturient or breastfeeding women
  • Persons deprived of liberty by judicial or administrative decision, person under legal protection
  • Refusal by a patient to do the PCA (anterior chamber puncture)
  • Patients whose following will be difficult or nonexistent

Sites / Locations

  • UniversityHospitalGrenoble

Arms of the Study

Arm 1

Arm Type

Other

Arm Label

Subjects suspected of toxoplasmosis chorioretinitis infection

Arm Description

Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection

Outcomes

Primary Outcome Measures

ELISA tests
ELISA (enzyme linked immunosorbent assay) tests. Biological markers evaluation : stress protein Hsp70 and antibodies anti-Hsp70.

Secondary Outcome Measures

Full Information

First Posted
July 21, 2016
Last Updated
July 22, 2016
Sponsor
University Hospital, Grenoble
search

1. Study Identification

Unique Protocol Identification Number
NCT02843438
Brief Title
Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis
Acronym
BIOLUVE
Official Title
Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis
Study Type
Interventional

2. Study Status

Record Verification Date
July 2016
Overall Recruitment Status
Completed
Study Start Date
January 2010 (undefined)
Primary Completion Date
January 2016 (Actual)
Study Completion Date
January 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University Hospital, Grenoble

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Toxoplasmosis affects one to two newborn each 10000 births. Among them, 1 to 2 % develop learning disabilities or die, and 4 to 27 % develop a chorioretinitis sometimes leading to an amblyopia responsible for visual impairment. Toxoplasmosis uveitis affects too adults immunocompetent and immunodepressed who have had an acquired toxoplasmosis. Clinical diagnosis of ocular toxoplasmosis is more complicated in presence of posterior neuro-retinitis, inflammation of the papilla, uveitis without chorioretinitis, fuchs heterochromic iridocyclitis, scleritis, diffuse necrotizing or multifocal retinitis. In this situation biological markers diagnostic and prognostic of toxoplasmosis uveitis are useful. Highly kept molecules (during evolution) like stress proteins (Hsp) are are found in the host and the pathogen and there can trigger a crossed immune response. Stress proteins haven't been explored yet, in the context of toxoplasmosis uveitis on humans. The hypothesis is that Hsp70 and antibodies anti-Hsp70 are diagnostic and prognostic markers of ocular toxoplasmosis. The goal is to evaluate diagnosis value of biological markers (Hsp70 and antibodies IgG anti-Hsp70) in toxoplasmosis uveitis.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subjects Clinically Suspected an Active Source of Toxoplasmosis Chorioretinitis Infection
Keywords
Toxoplasmosis, Uveitis, Chorioretinitis, Infection

7. Study Design

Primary Purpose
Screening
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
72 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Subjects suspected of toxoplasmosis chorioretinitis infection
Arm Type
Other
Arm Description
Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection
Intervention Type
Other
Intervention Name(s)
Fluorescein angiography
Intervention Type
Other
Intervention Name(s)
Dilated fundus examination
Intervention Type
Biological
Intervention Name(s)
Toxoplasmosis serology
Intervention Type
Drug
Intervention Name(s)
Anti-toxoplasmosis treatment
Intervention Type
Drug
Intervention Name(s)
Anti-inflammatory treatments
Intervention Type
Other
Intervention Name(s)
Puncture in anterior chamber
Primary Outcome Measure Information:
Title
ELISA tests
Description
ELISA (enzyme linked immunosorbent assay) tests. Biological markers evaluation : stress protein Hsp70 and antibodies anti-Hsp70.
Time Frame
About an hour

10. Eligibility

Maximum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age over 18 years Subjects clinically suspected at least of one active source of toxoplasmosis chorioretinitis infection Persons affiliated to national social security Exclusion Criteria: Pregnant, parturient or breastfeeding women Persons deprived of liberty by judicial or administrative decision, person under legal protection Refusal by a patient to do the PCA (anterior chamber puncture) Patients whose following will be difficult or nonexistent
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Laurence Bouillet, Professor
Organizational Affiliation
Grenoble Hospital University
Official's Role
Principal Investigator
Facility Information:
Facility Name
UniversityHospitalGrenoble
City
La Tronche
ZIP/Postal Code
38700
Country
France

12. IPD Sharing Statement

Citations:
PubMed Identifier
16282146
Citation
Bonfioli AA, Orefice F. Toxoplasmosis. Semin Ophthalmol. 2005 Jul-Sep;20(3):129-41. doi: 10.1080/08820530500231961.
Results Reference
background
PubMed Identifier
10880922
Citation
Bouillet L, Sarrot-Reynauld F, Gonzalvez B, Massot C, Romanet J, Mouillon M. [Diagnostic strategy in uveitis: a prospective study in 125 cases]. J Fr Ophtalmol. 2000 Jun;23(6):569-75. French.
Results Reference
background
PubMed Identifier
17645187
Citation
Brenier-Pinchart MP, Morand-Bui V, Fricker-Hidalgo H, Equy V, Marlu R, Pelloux H. Adapting a conventional PCR assay for Toxoplasma gondii detection to real-time quantitative PCR including a competitive internal control. Parasite. 2007 Jun;14(2):149-54. doi: 10.1051/parasite/2007142149.
Results Reference
background
PubMed Identifier
12502724
Citation
Chen M, Aosai F, Norose K, Mun HS, Yano A. The role of anti-HSP70 autoantibody-forming V(H)1-J(H)1 B-1 cells in Toxoplasma gondii-infected mice. Int Immunol. 2003 Jan;15(1):39-47. doi: 10.1093/intimm/dxg004.
Results Reference
background
PubMed Identifier
7650171
Citation
Chumpitazi BF, Boussaid A, Pelloux H, Racinet C, Bost M, Goullier-Fleuret A. Diagnosis of congenital toxoplasmosis by immunoblotting and relationship with other methods. J Clin Microbiol. 1995 Jun;33(6):1479-85. doi: 10.1128/jcm.33.6.1479-1485.1995.
Results Reference
background
PubMed Identifier
18696130
Citation
Chumpitazi BF, Bouillet L, Drouet MT, Kuhn L, Garin J, Zarski JP, Drouet C. Biological autoimmunity screening in hepatitis C patients by anti-HepG2 lysate and anti-heat shock protein 70.1 autoantibodies. Eur J Clin Microbiol Infect Dis. 2009 Feb;28(2):137-46. doi: 10.1007/s10096-008-0599-y. Epub 2008 Aug 12.
Results Reference
background
PubMed Identifier
18723143
Citation
Delair E, Monnet D, Grabar S, Dupouy-Camet J, Yera H, Brezin AP. Respective roles of acquired and congenital infections in presumed ocular toxoplasmosis. Am J Ophthalmol. 2008 Dec;146(6):851-5. doi: 10.1016/j.ajo.2008.06.027. Epub 2008 Aug 23.
Results Reference
background
Citation
Derouin F, Bultel C, Roze S. (Coordination rédactionnelle). Toxoplasmose: état des connaissances et évaluation du risque lié à l'alimentation. Rapport du groupe de travail " Toxoplasma gondii " de l'Afssa. Coordination éditoriale : Thomann C & Ribeiro F. AFSSA Déc. 2005, pp318.
Results Reference
background
PubMed Identifier
5924940
Citation
Desmonts G. Definitive serological diagnosis of ocular toxoplasmosis. Arch Ophthalmol. 1966 Dec;76(6):839-51. doi: 10.1001/archopht.1966.03850010841012. No abstract available.
Results Reference
background
PubMed Identifier
14727460
Citation
Direskeneli H, Saruhan-Direskeneli G. The role of heat shock proteins in Behcet's disease. Clin Exp Rheumatol. 2003 Jul-Aug;21(4 Suppl 30):S44-8.
Results Reference
background
PubMed Identifier
15967463
Citation
Echeverria PC, Matrajt M, Harb OS, Zappia MP, Costas MA, Roos DS, Dubremetz JF, Angel SO. Toxoplasma gondii Hsp90 is a potential drug target whose expression and subcellular localization are developmentally regulated. J Mol Biol. 2005 Jul 22;350(4):723-34. doi: 10.1016/j.jmb.2005.05.031.
Results Reference
background
PubMed Identifier
16943259
Citation
Fang H, Aosai F, Mun HS, Norose K, Ahmed AK, Furuya M, Yano A. Anaphylactic reaction induced by Toxoplasma gondii-derived heat shock protein 70. Int Immunol. 2006 Oct;18(10):1487-97. doi: 10.1093/intimm/dxl081. Epub 2006 Aug 30.
Results Reference
background
PubMed Identifier
10577593
Citation
Holland GN. Reconsidering the pathogenesis of ocular toxoplasmosis. Am J Ophthalmol. 1999 Oct;128(4):502-5. doi: 10.1016/s0002-9394(99)00263-9.
Results Reference
background
PubMed Identifier
15654837
Citation
Imamura Y, Kurokawa MS, Yoshikawa H, Nara K, Takada E, Masuda C, Tsukikawa S, Ozaki S, Matsuda T, Suzuki N. Involvement of Th1 cells and heat shock protein 60 in the pathogenesis of intestinal Behcet's disease. Clin Exp Immunol. 2005 Feb;139(2):371-8. doi: 10.1111/j.1365-2249.2005.02695.x.
Results Reference
background
PubMed Identifier
15906073
Citation
Kodjikian L, Wallon M, Fleury J, Denis P, Binquet C, Peyron F, Garweg JG. Ocular manifestations in congenital toxoplasmosis. Graefes Arch Clin Exp Ophthalmol. 2006 Jan;244(1):14-21. doi: 10.1007/s00417-005-1164-3. Epub 2005 May 20.
Results Reference
background
PubMed Identifier
8552407
Citation
Lyons RE, Johnson AM. Heat shock proteins of Toxoplasma gondii. Parasite Immunol. 1995 Jul;17(7):353-9. doi: 10.1111/j.1365-3024.1995.tb00902.x.
Results Reference
background
PubMed Identifier
18514029
Citation
Maubon D, Ajzenberg D, Brenier-Pinchart MP, Darde ML, Pelloux H. What are the respective host and parasite contributions to toxoplasmosis? Trends Parasitol. 2008 Jul;24(7):299-303. doi: 10.1016/j.pt.2008.03.012. Epub 2008 May 29.
Results Reference
background
PubMed Identifier
1836568
Citation
Pelloux H, Mouillon M, Romanet JP, Reynier P, Ligeon P, Goullier-Fleuret A, Ambroise-Thomas P. [Ocular toxoplasmosis. Comparison between two biological methods to study aqueous humor]. Presse Med. 1991 Oct 26;20(34):1655-8. French.
Results Reference
background
PubMed Identifier
16116161
Citation
Quintana FJ, Cohen IR. Heat shock proteins as endogenous adjuvants in sterile and septic inflammation. J Immunol. 2005 Sep 1;175(5):2777-82. doi: 10.4049/jimmunol.175.5.2777.
Results Reference
background
PubMed Identifier
15265933
Citation
SenGupta D, Norris PJ, Suscovich TJ, Hassan-Zahraee M, Moffett HF, Trocha A, Draenert R, Goulder PJ, Binder RJ, Levey DL, Walker BD, Srivastava PK, Brander C. Heat shock protein-mediated cross-presentation of exogenous HIV antigen on HLA class I and class II. J Immunol. 2004 Aug 1;173(3):1987-93. doi: 10.4049/jimmunol.173.3.1987.
Results Reference
background
PubMed Identifier
9673286
Citation
Silva NM, Gazzinelli RT, Silva DA, Ferro EA, Kasper LH, Mineo JR. Expression of Toxoplasma gondii-specific heat shock protein 70 during In vivo conversion of bradyzoites to tachyzoites. Infect Immun. 1998 Aug;66(8):3959-63. doi: 10.1128/IAI.66.8.3959-3963.1998.
Results Reference
background
PubMed Identifier
15965645
Citation
Wang XH, Qin Y, Hu MH, Xie Y. Dendritic cells pulsed with gp96-peptide complexes derived from human hepatocellular carcinoma (HCC) induce specific cytotoxic T lymphocytes. Cancer Immunol Immunother. 2005 Oct;54(10):971-80. doi: 10.1007/s00262-005-0662-9. Epub 2005 Jun 18.
Results Reference
background

Learn more about this trial

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

We'll reach out to this number within 24 hrs